Press Enter to search · Esc to close
A transplant drug has become the longevity movement's favorite gamble. Now clinical pharmacologists are saying, in plain language, that the evidence isn't there yet.
A 2025 analysis of 911 effect sizes asked which of longevity medicine's two favorite molecules truly mirrors dietary restriction. The answer reshuffles the conversation — carefully.
A reishi-derived compound matched rapamycin in worms and rejuvenated aged mice. A parallel review maps how machine learning is industrializing the search for the next generation of senolytics.
A cluster of 2024–2025 papers is dragging biological-age science out of the speculative zone and into the realm of measurable prediction. The signal is real — but so are the caveats.
A new whole-exome analysis of 1,245 long-lived Germans finds rare variants clustering in the mTOR pathway — the same one rapamycin targets — offering rare human evidence for a mechanism mostly studied in animals.